Dr. Perez Describes Retesting Recurrent Breast Cancer

Edith A. Perez, MD
Published: Tuesday, Feb 07, 2012

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the need to conduct new genetic assays in patients with recurrent breast cancer.

Perez states that preliminary data focused primarily on estrogen, progesterone, and HER2 receptors has shown a 20% change between the primary and metastatic setting. These changes make it necessary to conduct a second biopsy and a new set of molecular tests for recurrent tumors.

Currently assays focus on hormone receptor status and HER2; as targeted therapies continue to advance the need to conduct a full genome analysis will become necessary in order to fully predict the best treatment plan for patients.

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the need to conduct new genetic assays in patients with recurrent breast cancer.

Perez states that preliminary data focused primarily on estrogen, progesterone, and HER2 receptors has shown a 20% change between the primary and metastatic setting. These changes make it necessary to conduct a second biopsy and a new set of molecular tests for recurrent tumors.

Currently assays focus on hormone receptor status and HER2; as targeted therapies continue to advance the need to conduct a full genome analysis will become necessary in order to fully predict the best treatment plan for patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x